Isis partner Genzyme submits NDA for rare lipid disease drug
This article was originally published in Scrip
Executive Summary
Sanofi unit Genzyme took a leap forward in building its portfolio of lipid drugs by submitting its new drug application (NDA) for Kynamro (mipomersen sodium), a drug it licensed from partner Isis Pharmaceuticals, to the US FDA as a treatment for patients with homozygous familial hypercholesterolemia (HoFH), a rare, genetic cardiovascular disease.